NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Proteon Therapeutics, Inc. (NASDAQ:PRTO) concerning possible violations of federal securities laws. The investigation concerns whether Proteon made materially false and/or misleading statements and/or failed to disclose material information regarding its product candidate vonapanitase. Despite positive statements made regarding the efficacy and potential FDA approval of the drug, on December 13, 2016, Proteon announced that vonapanitase did not meet its primary endpoint in its first Phase 3 PATENCY-1 clinical trial. Following this news, shares of Proteon Therapeutics fell approximately 75% to close at $2.50 on December 12, 2016. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.